Heart Transplant in Alström Syndrome: When It's an Option

For people with Alström Syndrome whose cardiomyopathy progresses to end-stage heart failure despite optimal medical therapy, heart transplantation can be a life-saving option. Although Alström affects multiple body systems, transplant programs have successfully transplanted selected patients with Alström. This article covers when transplant is considered, what candidacy involves, and what life after transplant looks like.

Heart transplant is considered for patients with end-stage heart failure who:

• Have severe cardiac dysfunction (typically ejection fraction below 25%, or restrictive physiology with severe symptoms)
• Have exhausted standard medical therapy
• Have New York Heart Association class III or IV symptoms (significant limitation of physical activity)
• Are not expected to survive without transplant
• Are otherwise medically suitable for surgery

For patients with Alström specifically, candidacy considers:

• Severity and trajectory of cardiomyopathy
• Status of other Alström-related complications (kidney, liver, lungs)
• Overall life expectancy and quality-of-life considerations
• Patient and family preferences and ability to engage with post-transplant care¹

A transplant evaluation typically includes:

• Cardiac assessment — echocardiogram, cardiac MRI, right heart catheterization, exercise testing
• Other organ assessment — kidney function, liver function, lung function
• Infection screening
• Cancer screening
• Psychosocial evaluation
• Multidisciplinary review by transplant cardiology, surgery, and other specialties

For Alström patients, the multi-organ involvement is reviewed carefully. End-stage liver disease, severe kidney disease, or severe pulmonary disease may affect candidacy.²

Yes — case reports and small series describe successful heart transplantation in patients with Alström Syndrome. Outcomes have been generally favorable when other organ systems are reasonably preserved.³

The decision is individualized — Alström itself is not a contraindication to transplant, but the multi-system nature of the syndrome means each patient's situation requires careful assessment.

Surgery and immediate recovery

Heart transplant surgery typically lasts 4–6 hours under general anesthesia. The diseased heart is removed and replaced with the donor heart. Initial recovery in the ICU lasts days to weeks; total hospital stay is typically 2–4 weeks.

Lifelong immunosuppression

Recipients take immunosuppressive medications for the rest of their lives to prevent organ rejection. Common combinations include tacrolimus, mycophenolate mofetil, and prednisone. These medications:

• Reduce immune system activity
• Increase risk of infections
• Increase risk of certain cancers
• Affect kidney function over time
• Have specific side effects requiring monitoring

For Alström patients, the immunosuppression interaction with diabetes, kidney function, and other complications requires careful management.

Frequent monitoring

Post-transplant care includes:

• Regular endomyocardial biopsies (especially in the first year) to detect rejection
• Frequent blood tests for medication levels and organ function
• Regular cardiac imaging
• Vigilant infection prevention

Quality of life after transplant

Most successful transplant recipients return to substantial activity — employment, education, family life, exercise. Heart function is usually significantly better than pre-transplant. Life expectancy improves but remains limited compared to the general population.⁴

For patients waiting for transplant or as a destination therapy when transplant isn't an option, mechanical circulatory support devices like ventricular assist devices (VADs) can support the heart. Some patients with Alström have received VADs as bridge to transplant or as long-term therapy.

VAD therapy involves:

• Surgical implantation of a pump that supports the failing ventricle
• An external power source and controller worn by the patient
• Lifelong management with the VAD team

Some patients with Alström develop end-stage heart and kidney disease together. In selected cases, combined heart-kidney transplant is considered. This is rare but has been performed successfully in patients with multi-organ disease.

Decisions about pursuing heart transplant in someone with Alström involve:

• Cardiologist and transplant team assessment of medical suitability
• Patient and family values — quality of life, willingness to engage with intensive post-transplant care
• Realistic discussion of outcomes — transplant adds years and quality but isn't curative for the syndrome's other complications
• Coordination with other Alström specialists — kidney, liver, endocrinology

These discussions can take time and involve multiple visits before a decision is made.

For some patients, transplant isn't medically appropriate due to multi-organ disease, advanced age, or other factors. Alternative paths include:

• Optimized medical therapy with ongoing surveillance
• Mechanical circulatory support as destination therapy
• Palliative care integration alongside disease-directed therapy
• Symptom management and quality-of-life focus

These approaches can support meaningful life even without transplant, and patient organizations can connect families with others on this path.

• Dilated Cardiomyopathy in Infants With Alström Syndrome
• Adolescent and Adult Heart Disease in Alström Syndrome
• Heart Medications for Alström Syndrome
• Kidney Transplant and Dialysis in Alström Syndrome
• End-of-Life Care and Difficult Conversations in Alström

April 30, 2026.